Pneumococcal vaccine polyvalent

(Pneumovax 23®)

Pneumococcal vaccine polyvalent

Drug updated on 9/5/2024

Dosage FormInjection (intramuscular/subcutaneous; 0.5 mL)
Drug ClassVaccines
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Pneumovax 23 (pneumococcal vaccine polyvalent) is indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).
  • This summary is based on the review of six systematic review(s)/meta-analysis(es). [1-6]
  • PCV13: Demonstrated 75% efficacy against PCV13-type invasive pneumococcal disease (IPD) and 45% efficacy against PCV13-type pneumococcal pneumonia (PP) in one randomized controlled trial (RCT); observational studies showed effectiveness against PCV13-type IPD ranging from 47% to 68% and against PCV13-type PP ranging from 38% to 68%.
  • PPSV23: Pooled effectiveness was 45% (95% CI: 37%-51%) against PPSV23-type IPD (nine studies) and 18% (95% CI: -4%-35%) against PPSV23-type PP.
  • Dialysis Patients: No serious adverse effects reported.
  • PLWH: Immunogenicity improved with higher CD4 counts; no long-term safety data provided.
  • General Safety: Specific safety outcomes were not detailed in the studies. No specific safety concerns or adverse effects were noted in the studies for any specific population types or subgroups.
  • There is no population or subgroup information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Pneumovax (pneumococcal vaccine polyvalent) Prescribing Information.2023Merck Sharp & Dohme LLC, Rahway, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines